vs
Side-by-side financial comparison of APA Corporation (APA) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.2B, roughly 1.1× APA Corporation). Zoetis runs the higher net margin — 25.3% vs 15.0%, a 10.3% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -24.3%). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 1.4%).
APA Corporation, a holding company for Apache Corporation, an American company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Houston.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
APA vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $2.4B |
| Net Profit | $331.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 32.5% | 31.9% |
| Net Margin | 15.0% | 25.3% |
| Revenue YoY | -24.3% | 3.0% |
| Net Profit YoY | -22.1% | 3.8% |
| EPS (diluted) | $0.79 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $2.4B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.3B | $2.5B | ||
| Q1 25 | $2.7B | $2.2B | ||
| Q4 24 | $2.9B | $2.3B | ||
| Q3 24 | $2.7B | $2.4B | ||
| Q2 24 | $2.8B | $2.4B | ||
| Q1 24 | $2.1B | $2.2B |
| Q4 25 | $331.0M | $603.0M | ||
| Q3 25 | $205.0M | $721.0M | ||
| Q2 25 | $603.0M | $718.0M | ||
| Q1 25 | $418.0M | $631.0M | ||
| Q4 24 | $425.0M | $581.0M | ||
| Q3 24 | $-223.0M | $682.0M | ||
| Q2 24 | $541.0M | $624.0M | ||
| Q1 24 | $212.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 32.5% | 31.9% | ||
| Q3 25 | 33.7% | 37.0% | ||
| Q2 25 | 31.8% | 36.7% | ||
| Q1 25 | 31.9% | 36.5% | ||
| Q4 24 | 31.4% | 31.6% | ||
| Q3 24 | -5.2% | 36.6% | ||
| Q2 24 | 34.4% | 33.0% | ||
| Q1 24 | 32.2% | 34.1% |
| Q4 25 | 15.0% | 25.3% | ||
| Q3 25 | 9.0% | 30.0% | ||
| Q2 25 | 26.0% | 29.2% | ||
| Q1 25 | 15.4% | 28.4% | ||
| Q4 24 | 14.6% | 25.1% | ||
| Q3 24 | -8.1% | 28.6% | ||
| Q2 24 | 19.0% | 26.4% | ||
| Q1 24 | 9.9% | 27.4% |
| Q4 25 | $0.79 | $1.37 | ||
| Q3 25 | $0.57 | $1.63 | ||
| Q2 25 | $1.67 | $1.61 | ||
| Q1 25 | $0.96 | $1.41 | ||
| Q4 24 | $0.97 | $1.29 | ||
| Q3 24 | $-0.60 | $1.50 | ||
| Q2 24 | $1.46 | $1.37 | ||
| Q1 24 | $0.44 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $516.0M | — |
| Total DebtLower is stronger | $4.3B | — |
| Stockholders' EquityBook value | $6.1B | $3.3B |
| Total Assets | $17.8B | $15.5B |
| Debt / EquityLower = less leverage | 0.70× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $516.0M | — | ||
| Q3 25 | $475.0M | $2.1B | ||
| Q2 25 | $107.0M | $1.4B | ||
| Q1 25 | $67.0M | $1.7B | ||
| Q4 24 | $625.0M | $2.0B | ||
| Q3 24 | $64.0M | $1.7B | ||
| Q2 24 | $160.0M | $1.6B | ||
| Q1 24 | $102.0M | $2.0B |
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $4.3B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $5.2B | — |
| Q4 25 | $6.1B | $3.3B | ||
| Q3 25 | $6.0B | $5.4B | ||
| Q2 25 | $5.9B | $5.0B | ||
| Q1 25 | $5.4B | $4.7B | ||
| Q4 24 | $5.3B | $4.8B | ||
| Q3 24 | $5.1B | $5.2B | ||
| Q2 24 | $5.4B | $5.0B | ||
| Q1 24 | $2.6B | $5.1B |
| Q4 25 | $17.8B | $15.5B | ||
| Q3 25 | $17.7B | $15.2B | ||
| Q2 25 | $18.1B | $14.5B | ||
| Q1 25 | $18.5B | $14.1B | ||
| Q4 24 | $19.4B | $14.2B | ||
| Q3 24 | $19.4B | $14.4B | ||
| Q2 24 | $20.2B | $14.2B | ||
| Q1 24 | $15.0B | $14.3B |
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 1.13× | — | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.99× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $808.0M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | 2.44× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $808.0M | $893.0M | ||
| Q3 25 | $1.5B | $938.0M | ||
| Q2 25 | $1.2B | $486.0M | ||
| Q1 25 | $1.1B | $587.0M | ||
| Q4 24 | $1.0B | $905.0M | ||
| Q3 24 | $1.3B | $951.0M | ||
| Q2 24 | $877.0M | $502.0M | ||
| Q1 24 | $368.0M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | 2.44× | 1.48× | ||
| Q3 25 | 7.12× | 1.30× | ||
| Q2 25 | 1.96× | 0.68× | ||
| Q1 25 | 2.62× | 0.93× | ||
| Q4 24 | 2.44× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | 1.62× | 0.80× | ||
| Q1 24 | 1.74× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APA
| Oil And Gas Excluding Purchased | $1.7B | 76% |
| Oil And Gas Purchased | $323.0M | 15% |
| Oil Reserves | $114.0M | 5% |
| Other | $72.0M | 3% |
| Natural Gas Reserves | $30.0M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
